case report | Q2782326 |
scholarly article | Q13442814 |
P356 | DOI | 10.1128/AAC.02085-12 |
P8608 | Fatcat ID | release_djv3c2dzivfpzhbmkiqpb5lf7m |
P932 | PMC publication ID | 3632945 |
P698 | PubMed publication ID | 23439643 |
P50 | author | Roger J Brüggemann | Q88523388 |
Viola Christmann | Q57564453 | ||
Paul E. Verweij | Q70514014 | ||
Adilia Warris | Q73423823 | ||
P2093 | author name string | Jop Jans | |
P2860 | cites work | In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis | Q34150935 |
Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients | Q34932330 | ||
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion | Q35065709 | ||
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. | Q35689202 | ||
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. | Q37115709 | ||
Pharmacokinetics and safety of caspofungin in older infants and toddlers | Q37144851 | ||
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates | Q37320912 | ||
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms | Q41912237 | ||
In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species | Q42738793 | ||
Treatment of meningeal coccidioidomycosis with caspofungin | Q44931223 | ||
Caspofungin therapy of neonates with invasive candidiasis | Q45207584 | ||
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts | Q46812076 | ||
Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months | Q47354614 | ||
EUCAST technical note on anidulafungin | Q47577071 | ||
A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. | Q51185856 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | meningitis | Q48143 |
cerebrospinal fluid | Q54196 | ||
P304 | page(s) | 2391-2393 | |
P577 | publication date | 2013-02-25 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin | |
P478 | volume | 57 |
Q57476185 | Advances in the Treatment of Mycoses in Pediatric Patients |
Q38462784 | Impact of special patient populations on the pharmacokinetics of echinocandins. |
Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
Q41929675 | Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. |
Search more.